Details of the Drug

General Information of Drug (ID: DM8E3N6)

Drug Name

IPP-204106

Synonyms

NucAnt 6L; N-6-L; Nucleolin antagonist (cancer), ImmuPharma; Nucleolin antagonist (cancer), ImmuPharma/CNRS; Nucleolin antagonist (cancer), ImmuPharma/Centre National de la Recherche Scientifique

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[1]
------------------------------------------------------------------------------------

Cross-matching ID

TTD ID: D0Z1OR

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Nucleolin (NCL)	TTCSZH7	NUCL_HUMAN	Modulator	[2]
Nucleophosmin (NPM1)	TTHBS98	NPM_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Solid tumour/cancer

ICD Disease Classification

2A00-2F9Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Nucleolin (NCL)	DTT	NCL	3.15E-20	0.19	1.39

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT01711398) Dose-finding Adaptive Phase I/IIa Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IPP-204106N on Advanced Solid Tumors. U.S. National Institutes of Health.
2	Company report (ImmuPharma)